SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma

• Main Authors: Naomi Fei (Author), Sijin Wen (Author), Rajesh Ramanathan (Author), Melissa E. Hogg (Author), Amer H. Zureikat (Author), Michael T. Lotze (Author), Nathan Bahary (Author), Aatur D. Singhi (Author), Herbert J. Zeh (Author), Brian A. Boone (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract SMAD4, a tumor suppressor gene, is lost in up to 60%-90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling of macromolecules. Hydroxychloroquine (HCQ...